Search clinical trials for: U3-1784

Total 146 results

Daiichi Sankyo, Inc.

Terminated

An Open Study Assessing the Safety and Tolerability of U3-1784

Advanced Solid Tumors | Hepatocellular Cancer (HCC)

United Kingdom
Daiichi Sankyo, Inc.

Completed

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

Solid Tumors

United States
U3 Pharma GmbH

Completed

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Daiichi Sankyo, Inc.

Active, not recruiting

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Korea, Republic of, Netherlands, Taiwan, Japan
Washington University School of Medicine

Terminated

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Sarcoma | Lymphoma | Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
Daiichi Sankyo, Inc.

Completed

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors | Advanced Ovarian Cancer

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Melanoma | Head and Neck Cancer | Gastric Cancer | Advanced Solid Tumor

Japan
Intra-Cellular Therapies, Inc.

Not yet recruiting

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Healthy Volunteers

United States
Daiichi Sankyo

Available

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Daiichi Sankyo, Inc.

Recruiting

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

Chronic Kidney Disease
Daiichi Sankyo, Inc.

Terminated

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States, Spain, Belgium, Japan, France, United Kingdom, Italy, Poland
MegaPro Biomedical Co. Ltd.

Recruiting

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Solid Tumor, Unspecified, Adult

Taiwan
Bristol-Myers Squibb

Completed

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Shandong Suncadia Medicine Co., Ltd.

Active, not recruiting

Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects

Chronic Kidney Disease

China
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Japan
Samsung Medical Center

Not yet recruiting

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Solid Tumor, Adult

Korea, Republic of
AbbVie

Terminated

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Cancer | Non Small Cell Lung Cancer | Acute Myeloid Leukemia (AML)

United States, France, Israel, Japan, United Kingdom
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Ukraine, United Kingdom, United States, Bulgaria, Belgium, Germany, Hungary, Austria, Italy, Israel, Lithuania, Romania, Slovenia
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Massachusetts General Hospital

Completed

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Multiple Myeloma

United States
Massachusetts General Hospital
Exelixis

Completed

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Bile Duct Cancer | Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

Chronic Kidney Disease
Daiichi Sankyo, Inc.

Terminated

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Head and Neck Neoplasms

France, Hungary, United Kingdom, Belgium, Germany, Romania, Poland
Indiana University

Terminated

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Malignant Brain Tumor

United States
Daiichi Sankyo, Inc.

Completed

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United Kingdom
Centre Hospitalier Universitaire Dijon

Completed

Effects of OM-174 in Adult Patients With Solid Tumors (OM-174)

Solid Tumors
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Dana-Farber Cancer Institute

Completed

XL-184+Abiraterone in Post-Chemo CRPC

Prostate Cancer

United States
Daiichi Sankyo, Inc.
Parexel

Terminated

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)

Lung Cancer | Non-small Cell Lung Cancer

United States, Italy, Poland, United Kingdom, Belgium, Spain, Canada, Germany, Czechia, Hungary
Liza Villaruz, MD
Exelixis

Terminated

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Non Small Cell Lung Cancer (NSCLC) | Metastases to the Brain

United States
Lantern Pharma Inc.

Recruiting

Study of LP-184 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
SOLTI Breast Cancer Research Group
Daiichi Sankyo, Inc.

Active, not recruiting

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3)

Breast Cancer

Spain
Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
University of Rochester
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Recruiting

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Connect Biopharma Australia Pty Ltd

Completed

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

Healthy Adult Subjects

Australia
AHS Cancer Control Alberta
Cross Cancer Institute

Terminated

Metabolism of Lipids in Advanced Cancer

Lung Neoplasms | Cachexia

Canada
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreas Neoplasms

Japan
Daiichi Sankyo, Inc.

Terminated

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

Chile, Argentina
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States

Search clinical trials for: U3-1784

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations